Antiplatelet therapy—A pharmacologist's perspective  by Bultas, Jan
Available online at www.sciencedirect.comjournal homepage: www.elsevier.com/locate/crvasa
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 8 6 – e 9 40010-8650/$ - see fro
http://dx.doi.org/10.1
Tel.: þ420 775954
E-mail addressesReview Article—Special issue: ThrombosisAntiplatelet therapy—A pharmacologist’s perspectiveJan Bultas
Institute of Pharmacology, Third Faculty of Medicine, Charles University, Prague, Czech Republica r t i c l e i n f o
Article history:
Received 29 January 2013
Received in revised form
5 March 2013
Accepted 6 March 2013
Available online 13 March 2013
Keywords:
Antiplatelet agents
ADP receptor P2Y12 inhibitors
PAR-1 inhibitors
TXA2 synthesis inhibitors
5-HT receptor inhibitors
GP IIb/IIIa receptor inhibitorsnt matter & 2013 The Czec
016/j.crvasa.2013.03.003
471.
: jbult@lf1.cuni.cz, jbult@lfa b s t r a c t
There are only few areas of cardiology that have witnessed such dramatic innovations as that
occurring in the treatment and prophylaxis of thrombotic events. Antithrombotic (i.e., antiplate-
let and anticoagulation) therapy plays a pivotal role in the prophylaxis of the pandemic of
cardiovascular disease. Given the host of triggers activating primary hemostasis, various
therapeutic strategies are currently available. The current approach, monotherapy or dual therapy
or, possibly, combination therapy with antiplatelet and anticoagulant agents is selected based on
the risk of a thrombotic event, dominant disease, and the risk of bleeding.
The main problem associated with the current therapeutic strategy was not an insufﬁcient
effect, but major inter-individual variability of effect resulting in therapy failure or an
unacceptable risk of bleeding documented in a non-negligible proportion of patients. Hence
there is a drive for devising new antiplatelet strategies and innovation in (already) established
classes of drugs.
Milestones in the evolution of antiplatelet therapy included the advent of new, more effective
and/or safer antiplatelet agents inhibiting platelet activation. The new irreversible P2Y12 receptor
antagonist prasurgel and reversible P2Y12 receptor antagonist ticagrelor have been approved for
clinical use. There has also been major progress in the development of thrombin protease-
activated receptor 1 (PAR-1) antagonists (vorapaxar, atopaxar) or serotonin receptor blockers
(sarpogrelat). Another promising therapeutic strategy is targeted at platelet stabilization through
increased cyclic adenosine monophosphate (cAMP) activity by platelet phosphodiesterase-3
inhibition (cilostazol). Further, new insights into the bioavailability of acetylsalicylic acid under
speciﬁc conditions have been reported regarding the class of agents inhibiting thromboxane A2-
mediated activation.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All rights
reserved.
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A crucial role in the etiopathogenesis of cardiovascular events is
played by thrombosis. Activation of primary (platelet-based)
hemostasis is the key factor in the development of atherothrom-
botic events in the arterial bed whereas activation of hemocoa-
gulation underlies the development of thrombotic and
thromboembolic events in the venous system and cardiac cham-
bers. It clearly follows from the above that, while antiplatelet
therapy is crucial in conditions impairing arterial wall integrity
(prophylaxis of myocardial infarction, cerebrovascular events, and
critical limb ischemia), anticoagulation therapy is instituted in the
presence of blood stagnation (in atrial ﬁbrillation or in the venous
system at slow ﬂow rates). However, it should be always
remembered that the division into primary and secondary
hemostasis is arbitrary as both processes are intertwined. An
example of this is the phospholipid expression on the surface of
activated and aggregated platelets whereby an active surface will
enormously accelerate hemocoagulation. On the other hand,
thrombin, the key enzyme of the coagulation cascade, activates
platelets by stimulation of protease-activated receptors (PARs).
In fact, the main reason behind developing new therapeutic
strategies was not insufﬁcient efﬁcacy of available treatments; the
ambition was to obtain more advantageous pharmacological
properties. A major improvement was the more rapid onset of
action (obtained with prasugrel and ticagrelor or new direct
thrombin and factor Xa inhibitors). Another beneﬁt was a limited
duration of action (with the reversible P2Y12 receptor antagonist
ticagrelor). The former characteristic will be appreciated in acute
atherothrombotic states, the latter in bleeding. The third goal was
to obtain a more reliable effect in all patients regardless of their
pharmacogenetic makeup, that is, to minimize inter-individual
differences in their response to therapy. It was just this char-
acteristic that has actually contributed to the superiority of
prasugrel and ticagrelor over clopidogrel in terms of therapeutic
efﬁcacy. As suggested by analysis of Kaplan–Meier curves, the
beneﬁt of the more rapid onset of effect was smaller in this
context. Similarly, the more reliable anticoagulant action com-
bined with small variability in terms of an insufﬁcient or excess
effect has projected into enhanced efﬁcacy and safety proﬁles of
new direct thrombin and factor Xa inhibitors compared with
warfarin. Finally, the last advantage enhancing the image of novel
antithrombotics is their reduced propensity for drug interactions.
This is true not only when comparing new P2Y12 receptor
antagonists with clopidogrel, but also, when comparing new
anticoagulants with warfarin.
Antiplatelet agents include several classes of drugs differing in
their mode of action (Table 1). The current classiﬁcation of
antiplatelet drugs is used primarily for didactic reasons; in fact,
the modes of actions are closely interrelated as the activation of
the thromboxane/prostacyclin α receptor (TPα) by the vasodilators
prostaglandins I2 and E2 will suppress the effect of stimulation of
the P2Y12 receptor by adenosine diphosphate (ADP), TPβ receptor
by TXA2 and the protease activated receptor 1 (PAR-1) by
thrombin. The common place of action of the majority antiplatelet
drugs is adenylate cyclase activation (followed by cyclic adenosinemonophosphate synthesis and reduction in the ratio of phos-
phorylated to dephosphorylated vasodilator-stimulated phospho-
protein). Ratio of VASP/VASP-P determines the actual
thrombocyte activation/stabilization and GP IIb/IIIa receptor
stereoconformation (Fig. 1).
1.1. Inhibition of TXA2 synthesis by COX-1
blockade—aspirin and triﬂusal
The longest, and currently the most widely used strategy is
inhibition of thromboxane A2 (TXA2)-induced platelet activation.
There are two types of thromboxane/prostanoid (TP) receptors on
the platelet surface—TPα and TPβ. Activation of the receptor α
isoform (whose activators include prostacyclin and prostaglandin
E2) results in platelet stabilization whereas stimulation of the
receptor β isoform (with TXA2 as the primary ligand) activates the
thrombocyte (Fig. 2).
This class includes acetylsalicylic acid (aspirin) and triﬂusal,
both inhibiting TXA2 synthesis through cyclo-oxygenase-1 (COX-
1) blockade and the virtually unused TPβ receptor inhibitors. The
reduced TXA2 synthesis or inhibition of TP receptors (subtype β)
results in the expression of GP IIb/IIIa receptors at the level of
platelet and reduced activation and chemotaxis of the surround-
ing platelets. This is paralleled by stimulation of vasoconstriction
in the vascular smooth muscle and endothelial adhesion molecule
expression leading to activation of additional elements of blood,
in particular monocytes/macrophages [1,2]. Both aspirin and
triﬂusal inhibit platelet function by suppressing TXA2 synthesis
via preferential COX-1 inhibition; the effect on the isoenzyme
COX-2 is small.
As the evidence of the effect of aspirin was obtained under
clinical conditions different from the current ones, the risk of
potentially very frequent drug interactions or use of speciﬁc drug
forms should not be disregarded.
The mechanism of the antiplatelet action of aspirin is irrever-
sible inactivation of COX-1 in the platelet via serine acetylation in
the region of the enzyme's catalytic center. The result is inhibited
conversion of arachidonic acid to TXA2 precursors (intermediate
products—prostaglandins G2 and H2).
The critical process in producing the antiplatelet effect of
aspirin is resorption (Fig. 3). Acetylsalicylic acid (a weak hydro-
philic acid) will consistently resorb only in a non-dissociated state
(at a pH<3.5, i.e., in the acidic milieu of the stomach and proximal
duodenum). Platelet deactivation through COX-1 acetylation
occurs largely in portal blood; in the liver, the bulk of aspirin is
degraded to salicylic acid [3,4]. Salicylic acid also reduces the
activities of COX-1 and COX-2, but the effects are through actions
on nuclear factor κB (NF-κB) and inhibition is transient and is not
irreversible. Unless there is resorption in the stomach, aspirin
becomes de-acetylated by aspirin esterases in the intestines to
salicylic acid which (as a lipophilic molecule) will already absorb
well in the intestine. Because of the degradation by esterases and
variable resorption rates in the alkaline milieu, the resulting
concentration of aspirin in the portal circulation is unpredictable
and overall appreciably decreased [5,6]. Hence, we are faced with
a situation whereby one effect – irreversible inhibition of platelet
Table 1 – Overview of binding, activating and stabilizing platelet receptors, their ligands, and inhibitors.
Platelet receptor
Surface binding receptors Ligand Inhibitor
Collagen, Ib–IX–V receptors vWF, collagen ARC1779, ARC15105, ALX-0081 (clinical
evaluation)
Collagen, GPVI receptors Collagen JAQ1 (clinical evaluation)
Activating receptors Inductor Inhibitor
Thromboxane/prostaglandin TPβ
receptors
TXA2, PGH2, PGF2α TXA2 synthesis blockade (ASA,
triflusal), TXA2 and TPβ rec. synthesis
blockade (picotamide), TPβ rec.
blockade (terutroban, sulotroban—
development discontinued)
ADP, P2Y12 receptors ADP Reversible (ticagrelor, cangrelor) and
irreversible (clopidogrel, ticlopidine and
prasugrel) inhibitors
APD, P2Y1 receptors ADP MRS2500 (clinical evaluation)
Thrombin, PAR-1 receptors Thrombin Vorapaxar, atopaxar (clinical
evaluation)
Thrombin, PAR-4 receptors Thrombin Not known
Serotonin
(5-HT2A/2B) receptors
Serotonin Sarpogrelat (clinical evaluation),
naftidrofuryl
α-adrenergic receptors Noradrenaline α1-adrenergic receptor inhibitors
PAF receptors PAF (platelet-activating factor) Rupatadine, lexipafant (antiallergic
indication)
Stabilizing receptors Inductor Inhibitor
Adenosine, A2 receptors Adenosine Methylxanthines (caffeine,
aminophylline, etc.)
β-adrenergic, β2 receptors Adrenaline Non-selective beta-blockers
Thromboxane/prostaglandin TPα
receptors
ProstacyclinþPGE2 with analogs
(iloprost, trepostinil, epoprostenol,
alprostadil, limaprost)
Not known
Abbreviations: vWF—Von Willebrand factor, TXA2—thromboxane A2, PGH2—prostaglandine H2, PGF2α—prostaglandine F2α, PGE2—prostaglandine E2,
TP rec.—thromboxane-prostanoid receptor, ADP—adenosine-diphosphate, PAR—protease-activated receptor, 5-HT—5 hydroxy tryptamine (serotonine),
PAF—platelet-activating factor.
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Fig. 1 – Mechanism of action of different antiplatelet drugs. The critical point is the adenylate cyclase activation or inhibition and
cAMP production. In case of platelet phosphodiesterase-3 (PDE-3) inhibition by cilostasol, cAMP degradation is suppressed. By
modifying cAMP availability, cilostazol and dipyridamole may enhance the effect of ADP receptor blockers and COX-1 inhibitors.
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Fig. 2 – Cyclo-oxygenase pathway of platelet activation/inhibition by thromboxane A2 and prostacyclin or prostaglandin E2
synthesis. Stimulation of the target TPβ receptor by thromboxane A2 inhibits adenylate cyclase activity and induces platelet
aggregation. The inhibition of TXA2 activity could be achieved by COX-1 or TXA2 synthase inhibition or TPβ receptor
blockade.
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Fig. 3 – Mechanism of irreversible COX-1 thrombocyte inactivation in relation to absorption and degradation of aspirin in the
course of different stomach pHs. Acetylsalicylic acid, a weak hydrophilic acid, has an acid dissociation constant pKa of 3.5.
Aspirin will consistently resorb only in a non-dissociated state (at a pH<3.5) i.e., in the acidic milieu of the stomach and
proximal duodenum. Unless there is resorption in the stomach, aspirin becomes de-acetylated by aspirin esterases in the
intestines to salicylic acid, a lipophilic molecule, and will already absorb well in the intestine. Salicylic acid also reduces the
activity of COX-1 and COX-2, but the inhibition is short-lasting and reversible. Because of the aspirin degradation by
esterases and variable resorption rates in the alkaline milieu, the resulting concentration of aspirin in the portal circulation
is unpredictable and overall appreciably decreased. Platelet deactivation through COX-1 acetylation occurs largely in portal
blood; in the liver, the bulk of aspirin is degraded to salicylic acid.
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Fig. 4 – Adenosine diphosphate pathway of platelet activation and relation to eicosanoid (TXA2 and PGI2/PGE2) effects.
Opposing effects of ADP (or TXA2) and prostacyclin/PGE2 on thrombocyte activation. Adenylate cyclase inhibition or
stimulation eventually results in a change in the ratio of phosphorylated to dephosphorylated protein VASP controlling
actual thrombocyte activation and GP IIb/IIIa receptor stereoconformation. The outcome is then also modified by other
nucleotide receptors, specifically namely P2Y1 receptor. Stimulation of the P2Y1 receptor induces calcium platelet
mobilization and calcium influx with a change in the thrombocyte shape and short-lasting thrombocyte activation.
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portal circulation by the actual parent molecule (acetylsalicylic
acid) and by the systemic anti-inﬂammatory and analgesic action
of its metabolite, salicylic acid. Should pH rise above 3.5 – as is the
case during co-administration of aspirin with proton pump
inhibitors (PPI) or administration of aspirin as enterosolvent
tablets – resorption in the stomach is impaired. It has been
suggested that aspirin concentrations in the portal circulation
remain at subtherapeutic levels. As studies published to date,
which documented an effect of aspirin in the prophylaxis of
atherothrombotic disease, did not use PPIs or involve the admin-
istration of drug presentations solvent in the acidic milieu, PPI co-
administration or use of enterosolvent tablets cannot be consid-
ered an “evidence-based strategy”. Although no prospective
controlled trials exploring modulation of the clinical impact of
co-medication are available, retrospective studies have documen-
ted an adverse impact. In this context, mention should be made of
a Danish registry showing that a combination of aspirin with a PPI
increased the incidence of vascular events and cardiovascular
mortality by 46% [7].
At the platelet level, the translocation of acetylsalicylic acid to
the cytoplasm is controlled by multidrug resistance protein-4
(MRP-4), an efﬂux pump whose higher activity decreases the
intracellular availability of aspirin. In addition to the pump's
functionally signiﬁcant polymorphism (with inter-individual dif-
ferences), its activity is largely affected intra-individually by drug
interactions or pathological conditions (e.g., extracorporeal sur-
gery or diabetes). Indeed, it is just the inhibition of MRP-4 by
dipyridamole which may explain why the effect of aspirin is
signiﬁcantly enhanced by dipyridamole. Its clinical relevance is
supported by MRP-4 upregulation seen in patients afterrevascularisation using coronary artery bypass grafting with a
several-fold increase in TXA2 production during aspirin-based
therapy and resumed inhibition of platelet synthesis after dipyr-
idamole administration [8].
The onset of effect following oral solvent aspirin occurs
quickly, within 20 min, and its plasma half-life is insigniﬁcant;
the effect is predominantly presystemic (i.e. in the portal circula-
tion). The antiplatelet effect persists as long as the platelets
remain in the circulation. As the antithrombotic action of anti-
platelet agents is believed to be optimal at inhibition of activation
of 60–90% platelets and, assuming the full effect lasts over a
period of 1–2 days, complete restoration of primary hemostasis
will occur within a week (Table 2).
A similar action is seen with triﬂusal, also a preferential COX-1
inhibitor causing irreversible serine acetylation at the active site
of the enzyme. Its advantage over aspirin is increased nitric oxide
(NO) availability via NO synthase stimulation [9]. Triﬂusal, whose
effect is likewise supported by a large body of evidence, is in use
in a number of European countries and the USA. While equally
effective, it is safer than acetylsalicylic acid and there is no
problem with bioavailability when co-medicated with PPIs.
Of the drugs approved and recommended in the recent
American College of Clinical Pharmacology (ACCP) guidelines,
mention should be made of picotamide, a combined TXA2 synth-
esis inhibitor (through the inhibition of thromboxane synthase, an
enzyme one step below COX) and inhibitor of type TPβ receptors
[10]. It has not yet been approved for clinical use in Europe.
Development of terutroban, a selective antagonist of the TPβ
receptor, has been discontinued. In secondary prevention it did
not show any superiority over aspirin in preventing ischemic
events.
Table 2 – Comparison of the effects of the most important antiplatelet drugs.
Drug Mechanism of
action/type of
bond
Route of
administration
Metabolic activation Plasma
half-life
Onset of
effect
Peak effect
achieved
Effect
wears
off
within
Clopidogrel P2Y12 rec.
inhibition/
irreversible
Oral CYP2C19 (sensitive
to CYP2C19
inhibition of type of
polymorphism)
≈6 h
(active
metabolite)
1–4 h
(loding dose
600 mg)
4–5 h
(loding
dose
600 mg)
≈week
Ticlopidine
P2Y12 rec.
inhibition/
irreversible
Oral CYP2C19 (sensitive
to CYP2C19
inhibition of type of
polymorphism)
7–13 h
(active
metabolite)
1–2 days 3–4 days ≈week
Prasugrel P2Y12 rec.
inhibition/
irreversible
Oral CYP3A4 and 2B6
(resistant to
inhibition or CYP
isoenzyme
polymorphism)
≈7 h (2–15)
(active
metabolite)
30 min 1–2 h in
fasting
state, 2–
3 h post-
prandially
≈week
Ticagrelor P2Y12 rec.
inhibition/
reversible
Oral Not necessary,
active metabolite
involved in the
effect by 1/4
6–13 h
(parent
drug and
active
metabolite)
30–60 min 1–2 h 1–2
days
Cangrelor
(being
evaluated)
P2Y12 rec.
inhibition/
reversible
Parenteral Not necessary 10–15 min Minutes 15 min 1 h
Vorapaxar
(being
evaluated)
PAR-1 rec.
inhibitor/
reversible
Oral Not necessary 165–310 h 30 min 2 h >8
weeks
Acetylsalicylic
acid (non-
entero-solvent
tablets)
Irreversible
COX1
blockade
(inhibition of
TXA2 synth.)
Oral and
parenteral
Not necessary 2–3 h <10 min with
i.v. admin,
20–30 min
with oral
route
1 h ≈week
Dipyridamole
(non-extended
released form)
Stimulation of
cAMP
synthesis
Oral Not necessary 8–15 h 1–2 h 2–4 h 1–2
days
Cilostazol Inhib. of
cAMP
degradation
(PDE-3 inhib.)
Oral Not necessary 11–13 h 1–2 h 2–3 h 1–2
days
Abciximab Inhib. of GP
IIb/IIIa rec.
(antibody)
Parenteral Not necessary 8–12 h Minutes Minutes 1–2
days
Eptiﬁbatide Inhib. of GP
IIb/IIIa rec.
(cyclopeptide)
Parenteral Not necessary 2–3 h Minutes Minutes 6–12 h
Tiroﬁbane Inhib. of GP
IIb/IIIa rec.
(non-peptide)
Parenteral Not necessary 1–2 h Minutes Minutes 5–10 h
Abbreviations: CYP—cytochrome P450; PON-1—paroxonase-1, PAR-1—protease-activated receptors; COX-1—cyclo-oxygenase 1, TXA2—thromboxane A2,
PDE—phosphodiesterase, cAMP—cyclic adenosine monophosphate.
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inhibitors (platelet P2Y12 receptor inhibitors)
Another class embraces inhibitors of adenosine diphosphate (ADP)-
induced activation, that is, platelet P2Y12 receptor inhibitors.Inhibition of the P2Y12 receptor entails lower availability of the
vasodilator-stimulated phosphoprotein (VASP) inducing stereo-
conformation changes in GP IIb/IIIa receptors, which facilitate
actual platelet aggregation. Increased production of the phos-
phorylated VASP form (VASP-P) results in platelet stabilization
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 8 6 – e 9 4e92(Fig. 4). This is paralleled, via a VASP-independent pathway, by
suppressed platelet degranulation. The crucial point in the path-
way leading to a change in the phosphorylated-to-
dephosphorylated ratio is adenylate cyclase activation and
increased cAMP availability.
Essentially, this class of antiaggregants is divided, based on the
type of inhibition, into irreversible (prasugrel, clopidogrel, and
ticlopidine) and reversible (ticagrelor) ones. Irreversible inhibitors
bind covalently to the platelet receptor thus deactivating it
permanently. Consequently, the platelet is unable to activate
ADP as long as it remains in circulation (even once the drug
concentration has decreased). By contrast, platelet inhibition by
the reversible inhibitor ticagrelor is dependent on the current
drug levels, and binding to platelet receptors is short term
(binding and dissociation occur within minutes); hence, platelet
function is quickly restored once the levels of the drug have
decreased.
Irreversible inhibitors are derived from thienopyridines and
should be bioactivated to pharmacologically effective metabolites.
The problemwith the ﬁrst- and second-generation thienopyridine
ADP receptor inhibitors (ticlopidine and clopidogrel) is their
complicated bioactivation taking hours to occur, even after the
administration of the loading dose. Moreover, in the case of
clopidogrel, conversion of 2-oxo-clopidogrel to an active thiol
metabolite depends on the rate of resorption by the glycoprotein
P (P-gp) efﬂux pump and the rate of bioconversion by CYP
isoenzymes, particularly CYP2C19 oxidase. Both systems are
polymorphous, a signiﬁcant percentage of the population has
genotypes with high or, conversely, low activity of both the
transport and metabolic systems. In cases where clopidogrel
bioavailability at the level of the intestine is low or the bulk of
clopidogrel undergoes degradation by esterases, the antiplatelet
effect is insufﬁcient. This condition is referred to as “high on-
treatment platelet reactivity”. Conversely, low P-gp activity or
hyperfunctional CYP2C19 oxidase polymorphisms signiﬁcantly
enhance the resultant pharmacological action of clopidogrel. In
the Caucasian population, heterozygote genotypes with lower, or
homozygote types with zero activity of CYP2C19 (CYP2C191/2,
1/3 and/or CYP2C192/2, 2/3, 3/3) occur in 20–30%,
genotypes with higher activity (CYP2C191/17 or CYP2C1917/
17) are found in about 20%; hyperfunctional or hypofunctional
P-gp genotypes (TT and/or CC ABCB1 polymorphism) occur
equally in an approximate 25% of the population, and half have
a genotype TC (intermediate activity pump). The resultant mosaic
of phenotypes affecting clopidogrel resorption and activation is
thus most varied [11,12].
Further, given the fact that bioavailability and activation are
modiﬁed by a variety of drug interactions, e.g., with proton pump
inhibitors (PPIs), antidepressants or steroid hormones, the
clopidogrel-treated population includes a wide spectrum of
patients with a varied response to therapy. In patients receiving
concomitant therapy with aspirin (i.e. the substantial proportion
of patients), an additional consideration is the variable availability
of aspirin due to frequent co-administration of dual antiplatelet
therapy with PPIs. It is quite logical then that trials exploring the
role of one or two factors fail to report consistent results.
The challenges posed by variable availability, bioactivation,
and slow onset of action in the class of irreversible ADP inhibitors
have been eliminated by the introduction of prasugrel. Its resorp-
tion and bioactivation are unproblematic and they are notmarkedly modulated by pharmacological effects or drug interac-
tions. The onset of action after a saturation dose is rapid, in the
order of tens of minutes. The duration of effect is dependent
mainly on platelet turnover, with full effect lasting 1–2 days, and
complete restoration of primary hemostasis occurring within 5–7
days (Table 2).
An innovation in the class ADP inhibitors came with the
introduction of reversible P2Y12 receptor inhibitors, speciﬁcally
ticagrelor. Ticagrelor, an adenosine derivative, is a competitive
ADP receptor blocker. The bulk of its action is mediated by the
mother molecule, and there is no need for bioactivation. The
inter- and intra-individual variability of effect is small. The onset
of effect is rapid, in the order of tens of minutes, and does not
persist beyond 24 h (Table 2). The shorter duration of action helps
reduce the risk of bleeding in the event of injury or need for
surgery; however, ticagrelor use requires increased cooperation
on the part of the patient.
Unlike the irreversible P2Y12 receptor inhibitors, ticagrelor has a
broader pharmacodynamic effect activating as it does also adenosine
receptors. Whether the effect is direct or mediated by a metabolite, or
whether ticagrelor stimulates adenosine release from erythrocytes, is
yet to be determined [13]. Whatever the case, the effects of adenosine
help explain some, ticagrelor-speciﬁc adverse effects. Stimulation of
A2B adenosine receptors activates the respiratory center and bronchial
muscle to contract, possibly resulting in dyspnea experienced over
the ﬁrst days after therapy initiation. Conversely, stimulation of
myocardial A1 and A2A receptors will slow the generation and
conduction of impulses, whose rate correlates with asymptomatic
pauses on ECG recordings, again typically only encountered within
the ﬁrst days of therapy.
When comparing ADP receptor blockers, the main advantages of
clopidogrel are lower direct health care costs while its drawbacks
include a slow onset of effect and major inter- and intra-individual
variability in its antiplatelet action. By contrast, both prasugrel and
ticagrelor have a rapid onset of effect, with prasugrel shown to have a
longer duration of effect while the effect of ticagrelor wears off earlier.
The former property is of advantage in patients reluctant to cooperate,
the latter in those at higher risk of bleeding or requiring surgery.
Compared with clopidogrel, both prasugrel and ticagrelor offer a more
consistent action and are effective in (up to a third) patients with a
reduced antiplatelet effect of clopidogrel; consequently, a higher risk
(again by a third) for bleeding is to be anticipated. When comparing
the efﬁcacy and safety proﬁles of prasugrel and ticagrelor, if indicated
in secondary prevention post-MI, their effect on reducing the
incidence of atherothrombotic events is equal and comparable with
the incidence of bleeding (if disregarding revascularisation-related
events). In patients scheduled for emergency surgical revascularisa-
tion, ticagrelor is signiﬁcantly safer. Adverse effects related to
adenosine receptor activation by ticagrelor usually occur within the
ﬁrst days of therapy, with dyspnea requiring therapy discontinuation
seen in only a small proportion of patients.
1.3. Drugs stabilizing the platelet by increasing cAMP
availability—dipyridamole and cilostazol
Increased availability of platelet cyclic adenosine monophosphate
(cAMP) blunts the response to various stimuli such as P2Y12
receptor activation inhibiting the effect of the key enzyme
adenylate cyclase. Increased cAMP availability can be obtained
by two opposite mechanisms, i.e., synthesis stimulation or
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increased cAMP activity, is obtained with dipyridamole (together
with P2Y12 receptor inhibitors), cilostazol is a powerful antagonist
of the platelet phosphodiesterase-3 (PDE-3) isoenzyme degrading
cAMP. Blockade of PDE-3 reduces the cAMP degradation and
increases the availability of this signal molecule. A higher cAMP
activity alters the ratio of the vasoactive VASP protein and its
phosphorylated form.
The other factor possibly contributing to the ultimate effect of
dipyridamole may be increased aspirin availability by inhibition of
multidrug resistance protein 1 (MRP-1). The MRP-1 is an efﬂux
pump expressed in thrombocytes. Higher MPR-1 activity (e.g. in
post-CABG patients or in diabetics) results in decreasing platelet
aspirin availability and insufﬁcient COX inhibition [8].
Both drugs – dipyridamole and cilostasol – have been shown
to exert a beneﬁcial effect in the secondary prevention of stroke;
their pharmacokinetic characteristics are shown in Table 2.
1.4. Thrombin PAR-1 receptor inhibitors and serotonin
5-HT2A and 5-HT2B receptor antagonists
Platelet activation is also mediated by a number of membrane
receptors listed (including their activators and inhibitors) in
Table 1. The most important ones – in clinical terms – are those
that can be effectively modulated.
This class of drugs is exempliﬁed by platelet protease-activated
receptors (PAR-1 and PAR-4). Their dominant ligand is thrombin;
platelet activation by thrombin serves as a link between second-
ary and primary hemostasis. The signiﬁcance of the PAR-1
receptor is complex—adenylate cyclase inhibition, platelet intra-
cellular Ca2þ mobilization and thrombocyte degranulation with
ADP release (Fig. 1, Ref. [14]).
At present, two PAR-1 inhibitors are being evaluated in clinical
trials in combination with ADP-induced activation inhibitors
or thromboxane-induced activation pathway inhibitors. While
vorapaxar has been through a series of Phase III trials, clinical
trials with atopaxar are still ongoing.
Vorapaxar, a selective reversible thrombin PAR-1 antagonist, has
been shown to have a rapid onset of action (within an hour) and long
duration of effect (t1/2 of 160 up to 310 h), allowing for a once-a-day
oral dosing regimen (following the administration of the loading
dose). Although the receptor blockade is reversible, the effect will
reliably last for several weeks (Table 2). This fact may be of critical
importance given the current unavailability of an antidote. As
vorapaxar elimination depends on CYP3A4 oxidase, signiﬁcant inter-
action with inhibitors and inductors of this isoenzyme is likely.
Another PAR-1 receptor inhibitor is atopaxar which, besides
blocking platelet activation, inhibits the release of endothelial acute
phase molecules, in particular of the cytokines interleukin-6,
sCD40L, and P-selectin [15]. As no effect of pharmacogenetics on
the resultant antiplatelet action has been demonstrated with
vorapaxar or atopaxar, and their availability was not modiﬁed by a
change in gastric pH value, there is no risk for interaction with PPIs.
Other receptors we have been able to modulate are platelet
serotonin receptors, speciﬁcally the 5-HT2A and 5-HT2B isoforms.
Their inhibition by sarpogrelat, an antagonist of both subtypes if
indicated as an antithrombotic, has been approved in a number of
Asian countries, but not in the EU. The other receptors, speciﬁcally
PAF or PAR-4, play only a supporting role and are thus not
expected to be indicated for primary hemostasis inhibition.1.5. Platelet GP IIb/IIIa receptor inhibitors
Inhibitors of aggregation as such are represented by glycoprotein (GP)
IIb/IIIa receptor blockers (abciximab, integrilin or tiroﬁban). Aggregation
occurs by ﬁbrinogen-forming ﬁbrin bridges between platelets follow-
ing GP IIb/IIIa receptor activation, the sequence of receptors is
occupied by bivalent proteins (ﬁbrin, Von Willebrand factor—vWF,
vitronectin, and others) resulting in primary thrombus formation.
Agents belonging to this class of drugs inhibit the last phase of
primary hemostasis. While the above listed classes suppress the
expression or stereoconﬁguration of these two membrane-bound
glycoprotein subunits, GP IIb/IIIa receptor antagonists prevent
platelets from binding together, a process mediated by bivalent
proteins containing the speciﬁc arginine–glycine–aspartate amino
acid sequence. The inhibition may be obtained using either
speciﬁc antibodies to receptors, which block bivalent protein
binding (abciximab) or peptides or non-peptide molecules occu-
pying their own domain (eptiﬁbatide or tiroﬁban).
Abciximab has been shown to have a strong and long-term
afﬁnity for the GP IIb/IIIa receptor, a plasma half-life of 8–12 h; its
effect thus wanes gradually lowering the risk for enhanced
hemostasis due to the rebound phenomenon. The cyclic hepta-
peptide eptiﬁbatide and the peptidomimetic molecule tiroﬁban
show a weaker afﬁnity for the receptor and have a shorter plasma
half-life (1–3 h); their action is thus shorter with hemostasis
returning to normal soon after infusion has been discontinued. As
both eptiﬁbatide and tiroﬁban are excreted via the kidney, renal
failure will prolong their effect.
Regarding the pharmacological effects, there have been
reports of inter-individual variability of the antithrombotic
response and risks of thrombosis and bleeding associated with
some types of GP IIb/IIIa receptor polymorphisms [16]. A number
of mutations at individual bases in the control genes or receptors
per se have been reported. While in vitro studies have linked many
of these single nucleotide polymorphisms to increased aggrega-
tion, other mutations have been associated with decreased
aggregation. The body of our knowledge is still not big enough
to make monitoring of GP IIb/IIIa receptors clinically relevant and
allow for targeted therapy.
In summary, development in the class of antiplatelet drugs has
made major advances over the last decade. However, the main
problem is not insufﬁcient efﬁcacy of drugs as, if using the optimal
dose and combination, hemostasis is inhibited; it is actually bleeding
complications which pose a problem. The variable antiplatelet action
of clopidogrel was eliminated when third-generation P2Y12 receptor
inhibitors had appeared on the scene.
It is thus no exaggeration to claim that, with the introduction
of ticagrelor- and prasugrel-based therapy, prophylaxis of throm-
botic events no longer resembles an unpredictable roulette game
with the physician unable to tell which patient will respond to
clopidogrel therapy, and has turned into a sophisticated chess
game with strictly deﬁned rules instead.
An issue to be yet solved is the availability of aspirin when co-
administered with proton pump inhibitors. The risk of failure of
dual antiplatelet therapy involving PPIs rests both with aspirin
and clopidogrel. The addition of a PPI to dual antiplatelet therapy
as well as the optimal antiplatelet combination should no doubt
be considered relative to the risks of thrombosis and bleeding. A
potential algorithm according to M.R. Thomas and R.F. Storey is
outlined in the schema shown below (Fig. 5, Ref. [17]).
Cardiovascular revent risk
high
coronary artery thrombosis on clopidogrel
(with/without stent), STEMI, diabetes, high
thrombocyte reactivity on clopidogrel, NSAD 
concomitant treatment, suboptimal stent 
insertion, high GRACE score, etc. 
low
elective coronary interventions with stent 
insertion, low thrombocyte reactivity on 
clopidogrel, low GRACE score
ticagrelor, prasugrel indication clopidogrel indication
Gastrointestinal bleeding risk
ticagrelor, prasugrel treatment
CRUSADE score, NSAD concomit. treatment, etc.
clopidogrel treatment
CRUSADE score, NSAD concomit. treatment,etc.
high middle low high middle low
any PPI avoid PPI rabeprazole, pantoprazole,
        H2 rec. inhibitors,
      Helicobacter pylori
             eradication
avoid PPI
Fig. 5 – Selection of the optimal ADP receptor inhibitor and indication of prophylactic proton pump inhibition according to
the risk of an atherothrombotic event and of bleeding.
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